Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 132.21% | 79.09% | -80.32% | 67.51% | -4.89% |
| Total Depreciation and Amortization | 0.79% | 0.67% | 0.32% | 0.29% | -0.95% |
| Total Amortization of Deferred Charges | 2.80% | -2.84% | 2.43% | 2.62% | -0.50% |
| Total Other Non-Cash Items | 52.62% | 12.72% | 23.25% | 27.30% | -30.64% |
| Change in Net Operating Assets | 189.16% | 25.53% | -1,849.58% | -170.33% | 119.90% |
| Cash from Operations | 10,027.47% | 101.81% | -607.90% | 123.78% | 19.74% |
| Capital Expenditure | 74.55% | -2,046.15% | 94.09% | -152.87% | 78.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 2.35% | 100.02% |
| Cash from Investing | 74.55% | -2,046.15% | -100.13% | 1.03% | 115.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 200.00% |
| Issuance of Common Stock | 695.12% | -62.93% | 761.88% | -- | -100.00% |
| Repurchase of Common Stock | 44.42% | 89.25% | -4,718.07% | -100.00% | -62.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -200.00% |
| Cash from Financing | 1,370.28% | 130.03% | -888.19% | 579.52% | -112.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,711.95% | 106.41% | -206.39% | 711.86% | 130.00% |